Drugs / HLD-0915
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06800313 | Feb 2025 → Apr 2028 expected | metastatic prostate carcinoma | Halda Therapeutics OpCo, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLD-0915 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06800313 ↗ |
| Known as | JNJ-101556143 | “Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer” NCT06800313 ↗ |
| Route | Oral | “safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of oral single-agent HLD-0915” NCT06800313 ↗ |